



Final Programme

Online Info session on the safety of cannabidiol as a novel food: data gaps and uncertainties

28 June 2022

14:30-15:00	Connection of participants to the platform	
15:00-15:10	Welcome and introduction to the event by the chair	Ana Afonso (EFSA -NIF)
15:10-16:25	Status of the safety assessment of CBD as Novel food Explanation of the Panel's statement <ul style="list-style-type: none"> • ADME, CBD interaction with drug metabolism (Q&A) • Gastrointestinal tract • Liver • Neurological, psychiatric and psychologic effects (Q&A) • Endocrine and Reprotox (Q&A) • Presence of small particles, including nanoparticles, or production of CBD as nanomaterial and CBD nano-formulation (Q&A) 	Annamaria Rossi (EFSA - NIF) Harry McArdle (NDA Panel) Harry McArdle (NDA Panel) Harry McArdle (NDA Panel) Inge Mangelsdorf (NDA Panel) Karen-Ildico Hirsch-Ernst (NDA Panel) Karen-Ildico Hirsch-Ernst (NDA Panel) Jose Vicente Tarazona (EFSA - MESE)
16:25-16:40	Requirements/instructions for future applications (Q&A)	Catalina Manieu (EFSA -FDP)
16:40-16:55	General Q&A	Chair WG/Panel
16:55-17:00	Concluding remarks & take-home messages	Chair WG/Panel